MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 05-16-2026
Ayala Pharmaceuticals Depreciation & Amortization 2011-2026 | AYLA
Annual Depreciation & Amortization Ayala Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 162 K | 168 K | 182 K | 150 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 182 K | 150 K | 166 K |
Quarterly Depreciation & Amortization Ayala Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 121 K | 81 K | 30 K | - | 140 K | 94 K | 164 K | - | 138 K | 89 K | 53 K | - | 47 K | 28 K | 20 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 164 K | 20 K | 83.8 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Happiness Biotech Group Limited
HAPP
|
380 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | China |
 |
AstraZeneca PLC
AZN
|
5.73 B | - | - | $ 96.9 B |  Britain |
 |
Athira Pharma
ATHA
|
972 K | - | - | $ 269 M | USA |
 |
Galera Therapeutics
GRTX
|
20 K | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
105 K | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
4.04 M | $ 33.32 | -4.81 % | $ 897 M | USA |
|
Forte Biosciences
FBRX
|
64 K | $ 22.02 | 0.09 % | $ 285 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | USA |
 |
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.73 | 4.85 % | $ 460 M | Britain |
 |
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | USA |
 |
Heron Therapeutics
HRTX
|
2.31 M | $ 0.87 | 0.41 % | $ 145 M | USA |
 |
Compugen Ltd.
CGEN
|
475 K | $ 2.79 | 6.9 % | $ 261 M |  Israel |
 |
Anika Therapeutics
ANIK
|
5.37 M | $ 14.78 | -1.63 % | $ 212 M | USA |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Incyte Corporation
INCY
|
93.3 M | $ 96.93 | -0.5 % | $ 18.9 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
24 K | $ 3.38 | -1.73 % | $ 5.56 M | Israel |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
122 K | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.64 | 4.46 % | $ 192 M | USA |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
7.72 M | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
700 K | $ 20.79 | -1.05 % | $ 2.65 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | USA |